| Literature DB >> 33117157 |
Shaobin He1,2, Jiaxing Tian3, Xiaodong Li2,4, Yana Zhou5, Mingzhong Xiao4, Ying Zhang6, Xiaojun Min7, Xiuyang Li8, Qing Zhang9, Yujiao Zheng3,10, Jia Ke11, Qingwei Li3, Junxiu Tao4, Ping Song12, Han Wang3, Yi Lv4, Qiyou Ding3,10, Shuang Tang3,10, Jiaran Lin3,10, Zhaoyuan Jiang12, Zijun Zhang12, Juexian Song13, Fengmei Lian3, Xiaolin Tong3.
Abstract
OBJECTIVE: During the follow-up of patients recovered from coronavirus disease 2019 (COVID-19) in the quarantine and observation period, some of the cured patients showed positive results again. The recurrent positive RT-PCR test results drew widespread concern. We observed a certain number of cured COVID-19 patients with positive RT-PCR test results and try to analyze the factors that caused the phenomenon.Entities:
Keywords: comprehensive intervention; coronavirus disease 2019; correlation factor analysis; positive RT-PCR test result; recurrence rate
Year: 2020 PMID: 33117157 PMCID: PMC7577046 DOI: 10.3389/fphar.2020.549117
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Flow chart of the observational research.
Characteristics of study observed person.
| Characteristic | All patients | Comprehensive intervention | No intervention | |
|---|---|---|---|---|
|
| ||||
| Median (IQR)-year | 56(43–63.75) | 54(42–62) | 58(48–68) | |
| Distribution-no./total no. (%; 95% CI) | ||||
| 0–14 years | 1/420(0.2; -0.2–0.7) | 0/325(0) | 1/95(1.1; -1.0–3.1) | |
| 15–49 years | 152/420(36.2;31.6–40.8) | 126/325(38.8;33.5–44.1) | 26/95(27.4; 18.4–36.3) | |
| 50–64 years | 172/420(41.0;36.2–45.7) | 139/325(42.8;37.4–48.1) | 33/95(34.7; 25.2–44.3) | |
| ≥65 yeats | 95/420(22.6;18.6–26.6) | 60/325(18.5;14.2–22.7) | 35/95(36.8; 27.1–46.5) | |
|
| ||||
| Female sex-no./total no. (%) | 213/420(50.7;45.9–55.5) | 160/325(49.2;43.8–54.7) | 53/95(55.8; 45.8–65.8) | |
|
| ||||
| Median (IQR)-kg/m2 | 24.05(21.99–26.02) | 24.06(21.97–26.18) | 24.03(22.49–25.48) | |
| Distribution-no./total no. (%; 95% CI) | ||||
| <18.5kg/m2 | 12/420(2.9;1.3–4.5) | 10/325(3.1;1.2–0.5) | 2/95(2.1; -0.8–5) | |
| 18.5 ≤ BMI<24kg/m2 | 189/420(45.0;40.2–49.8) | 145/325(44.6;39.2–50) | 44/95(46.3; 36.3–56.3) | |
| 24≤BMI<27kg/m2 | 146/420(34.8;30.2–39.3) | 111/325(34.2;29–39.3) | 35/95(36.8; 27.1–46.5) | |
| BMI≥27kg/m2 | 73/420(17.4;13.8–21) | 59/325(18.2;14–22.3) | 14/95(14.7; 7.6–21.9) | |
|
| ||||
| Median (IQR)-d | 40(33–43) | 39(33–43) | 40(35–44) | |
|
| ||||
| Total | 230/420(54.8; 50–59.5) | 167/325(51.4; 46.0–56.8) | 63/95(66.3; 56.8–75.8) | |
| Cough | 116/420(27.6; 23.3–31.9) | 82/325(25.2; 20.5–30.0) | 34/95(35.8; 21.6–45.4) | |
| Shortness of breath | 100/420(23.8; 19.7–27.9) | 75/325(23.1; 18.5–27.7) | 25/95(26.3; 17.5–35.2) | |
| Fatigue | 68/420(16.2; 12.7–19.7) | 54/325(16.6; 12.6–20.7) | 14/95(14.7; 7.6–21.9) | |
| Insomnia | 37/420(8.8; 6.1–11.5) | 8/325(2.5; 0.8–4.1) | 29/95(30.5; 21.3–39.8) | |
| Inappetence | 36/420(8.6; 5.9–11.2) | 26/325(8.0; 5.1–10.9) | 10/95(10.5; 4.4–16.7) | |
| Sweating | 30/420(7.1; 4.7–9.6) | 12/325(3.7; 1.6–5.7) | 18/95(18.9; 11.1–26.8) | |
| Diarrhea | 29/420(6.9; 4.5–9.3) | 22/325(6.8; 4–9.5) | 7/95(7.4; 2.1–12.6) | |
| Limb pain | 22/420(5.2; 3.1–7.4) | 22/325(6.8; 4–9.5) | – | |
| Thirsty | 18/420(4.3; 2.3–6.2) | 1/325(0.3; -0.3–0.9) | 17/95(17.9; 10.2–25.6) | |
| Nausea and vomiting | 15/420(3.6; 1.8–5.3) | 15/325(4.6; 2.3–6.9) | – | |
| Fever | 11/420(2.6; 1.1–4.1) | 11/325(3.4; 1.4–5.4) | 0/95(0) | |
| Constipation | 9/420(2.1; 0.8–3.5) | – | 9/95(9.5; 3.6–15.4) | |
| Fear of wind | 3/420(0.7; -0.1–1.5) | 2/325(0.6; -0.2–1.5) | 1/95(1.1; -1.0–3.1) | |
|
| ||||
| Total | 241/420(57.4; 52.7–62.1) | 173/325(53.2; 47.8–58.7) | 68/95(71.6; 62.5–80.6) | |
| Insomnia | 95/420(22.6; 18.6–26.6) | 63/325(19.4; 15.1–23.7) | 32/95(33.7; 24.2–43.2) | |
| Cough | 94/420(22.4; 18.4–26.4) | 63/325(19.4; 15.1–23.7) | 31/95(32.6; 23.2–42.1) | |
| Shortness of breath | 88/420(21.0; 17.1–24.8) | 55/325(16.9; 12.8–21.0) | 33/95(34.7; 25.2–44.3) | |
| Sweating | 69/420(16.4; 12.9–20) | 53/325(16.3; 12.3–20.3) | 16/95(16.8; 9.3–24.4) | |
| Expectoration | 55/420(13.1; 9.9–16.3) | 39/325(12.0; 8.5–15.5) | 16/95(16.8; 9.3–24.4) | |
| Thirsty | 52/420(12.4; 9.2–15.5) | 29/325(8.9; 5.8–12) | 23/95(24.2; 15.6–32.8) | |
| Fatigue | 38/420(9.0; 6.3–11.8) | 17/325(5.2; 2.8–7.7) | 21/95(22.1; 13.8–30.4) | |
| Diarrhea | 26/420(6.2; 3.9–8.5) | 16/325(4.9; 2.6–7.3) | 10/95(10.5; 4.4–16.7) | |
| Inappetence | 18/420(4.3; 2.3–6.2) | 10/325(3.1; 1.2–5.0) | 8/95(8.4; 2.8–14.0) | |
| Limb pain | 17/420(4.0; 2.2–5.9) | 17/325(5.2; 2.8–7.7) | – | |
| Constipation | 16/420(3.8; 2.0–5.6) | 5/325(1.5; 0.2–2.9) | 11/95(11.6; 5.1–18) | |
| Fever | 9/420(2.1; 0.8–3.5) | 3/325(0.9; -0.1–2.0) | 6/95(6.3; 1.4–11.2) | |
|
| ||||
| Total | 172/420(41.0; 36.2–45.7) | 119/325(36.6; 31.4–41.9) | 53/95(55.8; 45.8–65.8) | |
| Hypertension | 111/420(26.4; 22.2–30.6) | 87/325(26.8; 22–31.6) | 24/95(25.3; 16.5–34) | |
| Hyperlipidemia | 45/420(10.7; 7.8–13.7) | 35/325(10.8; 7.4–14.1) | 10/95(10.5; 4.4–16.7) | |
| Diabetes | 44/420(10.5; 7.5–13.4) | 31/325(9.5; 6.3–12.7) | 13/95(13.7; 6.8–20.6) | |
| Coronary heart disease | 23/420(5.5; 3.3–7.7) | 16/325(4.9; 2.6–7.3) | 7/95(7.4; 2.1–12.6) | |
| Hepatopathy | 13/420(3.1; 1.4–4.8) | 3/325(0.9; -0.1–2.0) | 10/95(10.5; 4.4–16.7) | |
| Chronic bronchitis | 12/420(2.9; 1.3–4.5) | 1/325(0.3; -0.3–0.9) | 11/95(11.6; 5.1–18) | |
| Hyperuricemia | 7/420(1.7; 0.4–2.9) | 7/325(2.2; 0.6–3.7) | – | |
| Malignant tumor | 6/420(1.4; 0.3–2.6) | 3/325(0.9; -0.1–2.0) | 3/95(3.2; -0.4–6.7) | |
| Chronic nephritis | 4/420(1.0; 0.0–1.9) | 1/325(0.3; -0.3–0.9) | 3/95(3.2; -0.4–6.7) | |
| Cerebral apoplexy | 4/420(1.0; 0.0–1.9) | 1/325(0.3; -0.3–0.9) | 3/95(3.2; 0.4–6.7) | |
|
| ||||
| Yes | 44/420(10.5; 7.5–13.4) | 35/325(10.8; 7.4–14.1) | 9/95(9.5; 3.6–15.4) | |
| No | 376/420(89.5; 86.6–92.5) | 290/325(89.2; 85.9–92.6) | 86/95(90.5; 84.6–96.4) | |
|
| ||||
| Yes | 44/420(10.5; 7.5–13.4) | 32/325(9.8; 6.6–13.1) | 12/95(12.6; 6.0–19.3) | |
| No | 376/420(89.5; 86.6–92.5) | 293/325(90.2; 86.9–93.4) | 83/95(87.4) | |
Comprehensive intervention and Positive RT-PCR test.
| All patients | Comprehensive intervention | No intervention | ||
|---|---|---|---|---|
|
| ||||
| Baduanjin exercise | 325/325(100) | |||
| Tongzhi granule | – | 294/325(90.5; 87.3–93.7) | – | |
| Wuhan Kangyi decoction | – | 39/325(12.0; 8.5–15.5) | – | |
| Moxibustion with acupoint application | – | 90/325(27.7; 22.8–32.6) | – | |
| Foot bath | – | 19/325(5.8; 3.3–8.4) | – | |
|
| 24/420(5.7; 3.5–7.9) | 9/325(2.8; 1.0–4.6) | 15/95(15.8; 8.5–23.1) | |
Univariate Analysis and Multivariate Analyses for the Positive RT-PCR test.
| Univariate Analyses | Multivariate analyses | |||
|---|---|---|---|---|
| P | OR (95% CI) | P | OR (95% CI) | |
| Management (comprehensive intervention vs. no intervention) | <0.001 | 0.152 (0.064, 0.360) | <0.0011 | 0.169 (0.070, 0.408) |
| <0.0012 | 0.169 (0.070, 0.408) | |||
| <0.0013 | 0.162 (0.066, 0.395) | |||
| <0.0014 | 0.169 (0.069, 0.412) | |||
| <0.0015 | 0.166 (0.067, 0.407) | |||
| <0.0016 | 0.165 (0.067, 0.406) | |||
| Sex (M vs. F) | 0.623 | 1.231 (0.538, 2.813) | 0.448 | 1.394 (0.592, 3.286) |
| 0.451 | 1.395 (0.587, 3.318) | |||
| 0.170 | 1.891 (0.760, 4.705) | |||
| 0.198 | 1.825 (0.730, 4.564) | |||
| 0.207 | 1.806 (0.721, 4.525) | |||
| 0.210 | 1.800 (0.718, 4.510) | |||
| Age | 0.026 | 1.040 (1.005, 1.076) | 0.127 | 1.026 (0.993, 1.062) |
| 0.129 | 1.026 (0.992, 1.062) | |||
| 0.093 | 1.030 (0.995, 1.065) | |||
| 0.189 | 1.024 (0.988, 1.062) | |||
| 0.184 | 1.025 (0.989, 1.062) | |||
| 0.183 | 1.025 (0.989, 1.062) | |||
| BMI | 0.999 | 1.000 (0.890, 1.123) | 0.988 | 0.999 (0.893, 1.118) |
| 0.913 | 0.994 (0.888, 1.112) | |||
| 0.755 | 0.981 (0.871, 1.105) | |||
| 0.716 | 0.978 (0.869, 1.102) | |||
| 0.704 | 0.977 (0.868, 1.101) | |||
| Smoking Status (Y vs N) | 0.998 | NA* | 0.997 | NA |
| 0.997 | NA | |||
| 0.997 | NA | |||
| 0.997 | NA | |||
| Alcohol Use (Y vs. N) | 0.725 | 0.766 (0.174, 3.374) | 0.951 | 0.951 (0.188, 4.804) |
| 0.998 | 0.998 (0.197, 5.051) | |||
| 0.958 | 1.045 (0.206, 5.309) | |||
| 0.946 | 1.058 (0.208, 5.373) | |||
*Estimators were not available because one cell contained zero value.
1Model included site, age and sex.
2Model included site, age, sex and BMI.
3Model included site, age, sex, BMI, smoking status and alcohol use.
4Model included site, age, sex, BMI, smoking status, alcohol use and disease history.
5Model included site, age, sex, BMI, smoking status, alcohol use, disease history and symptoms status when entering isolation site.
6Model included site, age, sex, BMI, smoking status, alcohol use, disease history, symptoms status when entering isolation site, and the duration from initial symptoms onset to nucleic retest.